RegulatoryCompany release

Cingulate says CTx-1301 ADHD resubmission awaits completion of CMC work after FDA rejection

🇺🇸 Cingulate Inc. (CING) · Tue 10 Nov 2026

The company's CEO said in a media interview that outstanding manufacturing work continues, with resubmission planned as promptly as practicable but no assurance on timing or approval.

Cingulate said on 10 November 2026 that its chief executive discussed, in a media interview, how the company is responding to the US Food and Drug Administration's Complete Response Letter on CTx-1301. The letter, dated 1 June 2026, concerned the new drug application for the ADHD candidate, which contains dexmethylphenidate hydrochloride.

According to the company, the chemistry, manufacturing and controls (CMC) work needed to address the agency's concerns is still under way. Cingulate said it intends to resubmit the application as promptly as practicable, but it gave no date and stressed there is no assurance on either timing or eventual approval.

The CEO also spoke about preparations for commercialisation. The company's summary does not provide further detail on those plans, and no specifics on the nature of the CMC deficiencies were available in the material reviewed.

As general context, a Complete Response Letter signals that the FDA has completed its review of an application but cannot approve it in its current form. A sponsor must address the listed deficiencies and resubmit, after which the agency assigns a new review goal date.

What it means for your team

  • Resubmission timing for CTx-1301 remains undefined; the company has not committed to a date, so planning assumptions should stay flexible.
  • The company frames the outstanding issues as CMC-related, a reminder that manufacturing and control readiness can decide the fate of an otherwise complete NDA.
  • Teams tracking the ADHD market should note that commercial preparation is continuing despite the regulatory delay, but approval is not assured.

Company's press release (SEC filing): Cingulate Inc. ↗

Article written by VigiEye from the official source (Cingulate Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →